THURSDAY, Oct. 15, 2020 — Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with type 2 diabetes and atherosclerotic
Read more
Home »
(HealthDay)—Patients with type 2 diabetes who develop obstructive sleep apnea (OSA) are at higher risk for cardiovascular disease (CVD) and other diabetes-related complications, according to
Read more
(HealthDay)—Younger people who are diagnosed with type 2 diabetes have higher weight and blood pressure (BP) than similarly aged people without diabetes, according to a
Read more